Craft

Anatara Lifesciences

Stock Price

$0.1

2024-10-04

Market Capitalization

$10.8 M

2024-10-04

Anatara Lifesciences Summary

Company Summary

Overview
Anatara Lifesciences is a company developing and commercializing products for gastrointestinal health. It specializes in the design of products for animal and human health. The company focuses on building a pipeline of products, including medicine addressing the chronic symptoms associated with irritable bowel syndrome (IBS) and the inflammatory bowel diseases in humans as well as a non-antibiotic therapy, Detach, that prevents and treats diarrhea disease in piglets.
Type
Public
Status
Active
Founded
2014
HQ
Carlton, AU | view all locations
Website
https://anataralifesciences.com/
Cybersecurity rating
Sectors

Key People

  • John Michailidis

    John Michailidis, Chief Operating Officer

    • Jane Ryan

      Jane Ryan, Non-Executive Director

      • Nicholas Haslam

        Nicholas Haslam, Non-Executive Director

        • David Brookes

          David Brookes, Executive Chairman

          LocationsView all

          1 location detected

          • Carlton, VIC HQ

            Australia

            level 3/62 Lygon St

          Anatara Lifesciences Financials

          Summary Financials

          Gross profit (H1, 2026)
          $178.0K
          Net income (H1, 2026)
          ($515.0K)
          Cash (H1, 2026)
          $1.1M
          EBIT (H1, 2026)
          ($513.0K)

          Footer menu